• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗生素使用对化疗免疫疗法疗效的影响取决于肿瘤反应性T细胞的来源。

The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.

作者信息

Kuczma Michal P, Ding Zhi-Chun, Li Tao, Habtetsion Tsadik, Chen Tingting, Hao Zhonglin, Bryan Locke, Singh Nagendra, Kochenderfer James N, Zhou Gang

机构信息

Georgia Cancer Center, Augusta University, Augusta, Georgia, USA.

Current/Present address: Institute for Biomedical Sciences, Georgia State University, Atlanta, Georgia, USA.

出版信息

Oncotarget. 2017 Dec 5;8(67):111931-111942. doi: 10.18632/oncotarget.22953. eCollection 2017 Dec 19.

DOI:10.18632/oncotarget.22953
PMID:29340102
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5762370/
Abstract

In recent years the combined use of chemotherapy and immunotherapy, collectively termed chemoimmunotherapy, has emerged as a promising treatment option for patients with cancer. Antibiotics are commonly used to reduce infection-related complications in patients undergoing chemotherapy. Intriguingly, accumulating evidence has implicated gut microbiota as a critical determinant of host antitumor immune responses, raising the question as to whether the use of broad-spectrum antibiotics would invariably diminish tumor response to chemoimmunotherapies. We investigated the impact of antibiotics on the therapeutic outcomes of cyclophosphamide (CTX) chemotherapy and adoptive T-cell therapy (ACT) where CTX was used as the host-conditioning regimen in mice. We show that antibiotic prophylaxis dampened the endogenous T cell responses elicited by CTX, and reduced the efficacy of CTX against B-cell lymphoma. In the ACT setting, antibiotics administration impaired the therapeutic effects of adoptively transferred tumor-specific CD4+ T cells in mice with implanted colorectal tumors. In contrast, long-term antibiotic exposure did not affect the efficacy of ACT using CD19-targeting chimeric antigen receptor (CAR) T cells in mice with systemic B-cell lymphoma, although it correlated with prolonged CAR expression and sustained B-cell aplasia. Our study demonstrates that chemoimmunotherapies may have variable reliance on intestinal microbiota for T cell activation and function, and thus have different sensitivities to antibiotic prophylaxis. These findings may have implications for the judicial use of antibiotics in cancer patients receiving chemoimmunotherapies.

摘要

近年来,化疗与免疫疗法的联合应用,统称为化学免疫疗法,已成为癌症患者一种有前景的治疗选择。抗生素常用于降低接受化疗患者的感染相关并发症。有趣的是,越来越多的证据表明肠道微生物群是宿主抗肿瘤免疫反应的关键决定因素,这就引发了一个问题,即使用广谱抗生素是否会不可避免地降低肿瘤对化学免疫疗法的反应。我们研究了抗生素对环磷酰胺(CTX)化疗和过继性T细胞疗法(ACT)治疗效果的影响,其中在小鼠中将CTX用作宿主预处理方案。我们发现抗生素预防抑制了CTX引发的内源性T细胞反应,并降低了CTX对B细胞淋巴瘤的疗效。在ACT环境中,抗生素给药损害了植入结直肠癌小鼠中过继转移的肿瘤特异性CD4 + T细胞的治疗效果。相比之下,长期接触抗生素并不影响在患有全身性B细胞淋巴瘤的小鼠中使用靶向CD19的嵌合抗原受体(CAR)T细胞进行ACT的疗效,尽管这与CAR表达延长和持续的B细胞发育不全相关。我们的研究表明,化学免疫疗法对肠道微生物群进行T细胞激活和功能的依赖可能各不相同,因此对抗生素预防具有不同的敏感性。这些发现可能对接受化学免疫疗法的癌症患者合理使用抗生素具有启示意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/f4c62c40d36d/oncotarget-08-111931-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/78a7ab5159b9/oncotarget-08-111931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/63a7e4b97dcb/oncotarget-08-111931-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/0a1ae75edc28/oncotarget-08-111931-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/61ccca23951d/oncotarget-08-111931-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/f4c62c40d36d/oncotarget-08-111931-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/78a7ab5159b9/oncotarget-08-111931-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/63a7e4b97dcb/oncotarget-08-111931-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/0a1ae75edc28/oncotarget-08-111931-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/61ccca23951d/oncotarget-08-111931-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/47e8/5762370/f4c62c40d36d/oncotarget-08-111931-g005.jpg

相似文献

1
The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.抗生素使用对化疗免疫疗法疗效的影响取决于肿瘤反应性T细胞的来源。
Oncotarget. 2017 Dec 5;8(67):111931-111942. doi: 10.18632/oncotarget.22953. eCollection 2017 Dec 19.
2
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.环磷酰胺诱导的旁观者效应在小鼠过继性免疫治疗中对成功根除肿瘤的T细胞的重要性。
J Clin Invest. 1998 Jan 15;101(2):429-41. doi: 10.1172/JCI1348.
3
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration.环磷酰胺通过诱导细胞因子表达、B细胞和T细胞稳态增殖以及特异性肿瘤浸润,增强过继性转移免疫细胞的抗肿瘤疗效。
Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):644-53. doi: 10.1158/1078-0432.CCR-06-1209.
4
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.通过CD19特异性嵌合抗原受体提供的CD28共刺激增强了过继转移T细胞在体内的持久性和抗肿瘤功效。
Cancer Res. 2006 Nov 15;66(22):10995-1004. doi: 10.1158/0008-5472.CAN-06-0160.
5
CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells.巨细胞病毒pp65疫苗增强了过继转移的CD19定向巨细胞病毒特异性T细胞的抗肿瘤功效。
Clin Cancer Res. 2015 Jul 1;21(13):2993-3002. doi: 10.1158/1078-0432.CCR-14-2920. Epub 2015 Apr 2.
6
Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide.通过对环磷酰胺反应的基因和蛋白质表达谱进行分析,揭示癌症化疗免疫治疗的机制。
Cancer Res. 2011 May 15;71(10):3528-39. doi: 10.1158/0008-5472.CAN-10-4523. Epub 2011 Mar 28.
7
Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.定义环磷酰胺预处理增强抗原特异性CD8 + T细胞对肽疫苗反应的能力:创建一个涉及I型干扰素和髓样细胞的有益宿主微环境。
J Immunother. 2007 Jan;30(1):40-53. doi: 10.1097/01.cji.0000211311.28739.e3.
8
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.Toll 样受体激动剂治疗可以在不进行宿主预处理的情况下,显著增强过继转移的 CD8(+)T 细胞的抗肿瘤活性。
J Immunother Cancer. 2016 Feb 16;4:6. doi: 10.1186/s40425-016-0110-8. eCollection 2016.
9
Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells.烷基化剂美法仑可增强使用肿瘤特异性CD4 + T细胞的过继性免疫疗法的疗效。
J Immunol. 2015 Feb 15;194(4):2011-21. doi: 10.4049/jimmunol.1401894. Epub 2015 Jan 5.
10
Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.CD19 抗原的自然表达会影响 CD19 特异性工程 T 细胞的长期植入,但不会影响其抗肿瘤活性。
J Immunol. 2010 Feb 15;184(4):1885-96. doi: 10.4049/jimmunol.0901440. Epub 2010 Jan 20.

引用本文的文献

1
Challenges in the preclinical design and assessment of CAR-T cells.嵌合抗原受体T细胞(CAR-T细胞)临床前设计与评估中的挑战。
Front Immunol. 2025 Aug 8;16:1564998. doi: 10.3389/fimmu.2025.1564998. eCollection 2025.
2
Pharmacovigilance analysis of secondary primary malignancies and antibiotic interactions in CAR-T cell therapies.嵌合抗原受体T细胞疗法中继发性原发性恶性肿瘤与抗生素相互作用的药物警戒分析
Ther Adv Drug Saf. 2025 Jun 5;16:20420986251340866. doi: 10.1177/20420986251340866. eCollection 2025.
3
The Role of the Gut Microbiome in Non-Hodgkin Lymphoma (NHL): A Focus on Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Cutaneous T-Cell Lymphoma, and NK/T-Cell Lymphoma.

本文引用的文献

1
Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.屎肠球菌和人肠球菌有助于环磷酰胺诱导的治疗性免疫调节作用。
Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.
2
IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.白细胞介素-7信号传导赋予CD4(+) T细胞多功能性和干性潜能。
Oncoimmunology. 2016 Apr 25;5(6):e1171445. doi: 10.1080/2162402X.2016.1171445. eCollection 2016 Jun.
3
Efficacy of antineoplastic treatment is associated with the use of antibiotics that modulate intestinal microbiota.
肠道微生物群在非霍奇金淋巴瘤(NHL)中的作用:聚焦弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤、皮肤T细胞淋巴瘤和NK/T细胞淋巴瘤。
Cancers (Basel). 2025 May 20;17(10):1709. doi: 10.3390/cancers17101709.
4
Antibiotic use: impact on the microbiome and cellular therapy outcomes.抗生素的使用:对微生物群和细胞治疗结果的影响。
Blood Adv. 2025 Jul 8;9(13):3356-3367. doi: 10.1182/bloodadvances.2024013809.
5
Unraveling the Anti-Cancer Mechanisms of Antibiotics: Current Insights, Controversies, and Future Perspectives.解析抗生素的抗癌机制:当前见解、争议及未来展望
Antibiotics (Basel). 2024 Dec 25;14(1):9. doi: 10.3390/antibiotics14010009.
6
The intestinal microbiota and cellular therapy: implications for impact and mechanisms.肠道微生物群和细胞治疗:影响和机制的意义。
Blood. 2024 Oct 10;144(15):1557-1569. doi: 10.1182/blood.2024024219.
7
Reversal of Platinum-based Chemotherapy Resistance in Ovarian Cancer by Naringin Through Modulation of The Gut Microbiota in a Humanized Nude Mouse Model.柚皮苷通过调节人源化裸鼠模型中的肠道菌群逆转卵巢癌铂类化疗耐药性
J Cancer. 2024 Jun 11;15(13):4430-4447. doi: 10.7150/jca.96448. eCollection 2024.
8
Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease.血与内脏:肠道微生物组如何塑造造血和血液病治疗。
Blood. 2024 Apr 25;143(17):1689-1701. doi: 10.1182/blood.2023021174.
9
The critical role of tumor microbiome in cancer immunotherapy.肿瘤微生物组在癌症免疫治疗中的关键作用。
Cancer Biol Ther. 2024 Dec 31;25(1):2301801. doi: 10.1080/15384047.2024.2301801. Epub 2024 Jan 19.
10
Bifidobacterium affects antitumor efficacy of oncolytic adenovirus in a mouse model of melanoma.双歧杆菌对溶瘤腺病毒在黑色素瘤小鼠模型中的抗肿瘤疗效有影响。
iScience. 2023 Aug 19;26(10):107668. doi: 10.1016/j.isci.2023.107668. eCollection 2023 Oct 20.
抗肿瘤治疗的疗效与使用调节肠道微生物群的抗生素有关。
Oncoimmunology. 2016 Apr 22;5(6):e1150399. doi: 10.1080/2162402X.2016.1150399. eCollection 2016 Jun.
4
The microbiota in adaptive immune homeostasis and disease.适应性免疫稳态和疾病中的微生物组。
Nature. 2016 Jul 7;535(7610):75-84. doi: 10.1038/nature18848.
5
An essential role of Ffar2 (Gpr43) in dietary fibre-mediated promotion of healthy composition of gut microbiota and suppression of intestinal carcinogenesis.游离脂肪酸受体2(Gpr43)在膳食纤维介导的促进肠道微生物群健康组成和抑制肠道癌变中的重要作用。
Oncogenesis. 2016 Jun 27;5(6):e238. doi: 10.1038/oncsis.2016.38.
6
Medical management of side effects related to CAR T cell therapy in hematologic malignancies.血液系统恶性肿瘤中与CAR T细胞疗法相关的副作用的医学管理。
Expert Rev Hematol. 2016 Jun;9(6):511-3. doi: 10.1080/17474086.2016.1183479. Epub 2016 May 19.
7
Microbiome and Anticancer Immunosurveillance.微生物组与抗肿瘤免疫监视
Cell. 2016 Apr 7;165(2):276-87. doi: 10.1016/j.cell.2016.03.001.
8
The role of microbiota in cancer therapy.微生物群在癌症治疗中的作用。
Curr Opin Immunol. 2016 Apr;39:75-81. doi: 10.1016/j.coi.2016.01.003. Epub 2016 Jan 26.
9
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.通过CTLA-4阻断进行的抗癌免疫疗法依赖于肠道微生物群。
Science. 2015 Nov 27;350(6264):1079-84. doi: 10.1126/science.aad1329. Epub 2015 Nov 5.
10
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.共生双歧杆菌可促进抗肿瘤免疫并增强抗程序性死亡受体配体1(PD-L1)的疗效。
Science. 2015 Nov 27;350(6264):1084-9. doi: 10.1126/science.aac4255. Epub 2015 Nov 5.